# NCI-NRG ALK Protocol (NCT03737994)

> Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: alectinib; brigatinib; lorlatinib
- Indication: previously treated ALK-positive stage IV non-squamous NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03737994
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: National Cancer Institute (NCI)
- Conditions: Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
- Interventions: Alectinib; Brigatinib; Carboplatin; Ceritinib; Cisplatin; Crizotinib; Ensartinib; Lorlatinib; Pemetrexed
- Enrollment: 10
- Primary outcome: Objective Response Rate (ORR), Per Investigator Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria

## Indexed commentary on NCI-NRG ALK Protocol so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nci-nrg-alk-protocol-nct03737994